IGC Pharma, Inc. (New York Stock Exchange Arca:IGC)
| Market Cap | 28.03M-34.0% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 100.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | 0.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 3 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About IGC
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
$IGC stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IGC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IGC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IGC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IGC Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IGC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IGC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IGC
| ETF | Est. Holding Size |
|---|---|
| PSILAdvisorShares Psychedelics ETF | $256.82K |
| VXFVanguard Extended Market ETF | $243.82K |
Estimated from each fund’s disclosed top holdings × AUM
IGC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IGC’s recent data — informational, not investment advice